NL1015352C2 - Antigen conjugation vaccination technique with host virus. - Google Patents

Description

Antigen conjugation vaccination technique with host virus AIDS is caused by a lentivirus that is part of the retrovirus family. The discovery of the causes of retrovirus is thanks to L. Montagnier, F.

5 Barre-Sinoussi and J.C. Cherman. Properties of an AIDS infection are well known. (Luc. Montagnier and Francois Clavel, Institute Pasterur, Paris, France).

The adult AIDS retrovirus has a diameter between 100 nm and 120 nm. The unit virion is a sphere in shape. AIDS retrovirus genome is quite well known. (Gallo, 1995, Nat. Med., 1: 753-759).

10 The adult AIDS retrovirus has been circulated at an average of 80

Spikes. These Spikes contain glycol protemps. (Luc Montagnier and Francois Clavel, Institute Pasterur, Paris, France).

For further AIDS virus information see; (Ho et al., 1995, Nature, 373: 123-126; Wei et al., 1995, Nature 373: 117-122).

This invention contains a vaccination preparation and administration instruction directly related to the treatment of viruses, especially the HIV retrovirus, with host healing as an objective purpose. This vaccination preparation consists of a number of parts that are described here. The sequence is logical and chronological. Then another administrative conclusion is indicated.

The presented invention explains how to make a conjugation antigen complex derived from a mixture between acrolein and the host specific virus. That this antigen vector can then be used as an immune system catalysis for the specific host from which the original virus template originates. This invention has been indicated as a technique to cure infected patients through the removal of their own virus via the acroleinized virus to be used as a catalysis.

The naturally occurring and synthesized liquid chemical Acrolein is essential in this invention. Acrolein is also known as H2C-CH-OH, Acrylaldehyde, 2-propenal or C3H40. See Describe Acrolein Complete. It is classified as a "fixative or modifying reagent". Acrolein is extremely unstable and cannot sustain its characteristic for 30 years. Acrolein appears to have very high hygienic properties. This fact is discovered by accident. (Windows, PSEBM, 1949 72, 18-21).

The use of acrolein in this invention is based on research work that has taken place in 1948-49. During unsightly trauma such as branding and severe injury the body produced small amounts of acrolein. Research shows that 1015352 will be able to combine 2 acrolein with human serum as animal serum. When the combination is tested for antibody, it is said that the combination does not cause an anti-immune response. Further research in these directions has provided results that indicate that the acrolein caused no change in the base molecular configuration of the proteins examined. (Kamen, PSEBM, 1949, 72, 18-21).

During research it is noticed that protein serum underwent the same kind of molecular change. This fact remains the same despite the protein's original molecular structure. This finding provides an indication that acrolein makes the same kind of connection with the proteins. The suspected compound is via the NH2, Indole groups and or amino10 groups (Kamen, PSEBM, 1949, 72 18-21).

Later research indicated that Mengo and Semlici Forest virus could be deactivated with acrolein and further that they could be used as a vaccine. Despite this, the viruses showed completely different morphological exterior 100% immunization logs after the injection regimen knife. (Kamen, Nature, Vol. 192, No. 4806, pp. 986-987, Dec 9 1961).

15 The definition of “Fixation of Acroleinization, Acroleinized Acroleinize process further indicated in the text as F AA” is as followed. "F AA is the act of creating an artificial conjugation consisting of the host specific retrovirus and the chemistry acrolein. FAA would also have been considered terms for the conjugation process.

Definition of "Spike (s)" is as follow. The extremity of a virus that is attached to the virus via the virus envelope or capsid upper surface. This "spike" is also called the "discrete functional unit" and or "trimers" in adult viruses. Retrovirus spikes are made up of a number of glycol proteins. They have often been given the following names: gpl60, gpl20, gp41, gp36, gpl25, gpl40. Each Spike chain of proteins contains two types of molecular macro shapes. A protein shape is helical and concentrated in length and a second shape has an unimaginable fold. Glycoproteins are fixed on the protein region. The fact that Spikes consist of glycoproteins is essential to this invention mechanism.

It has been proposed in connection with this invention that the 3-4 Angstrum acrolein chain blocked the entire virus "spike" by circling it. The three carbon acrolein 30 chain causes a spike blockage that gives the host immune system a chance to activate the recognition process. A suggestion of this process is that the carbon chain provides coverage over the entire surface of the virus.

Further,. Antibody production is then based on the original host virus template which is morphologically identical except that it is somewhat thicker than the normal 1015352 3 virus. The acrolein-host combination creates a morphologically identical unit. It is further suggested that the virus is no longer alive at the time of injection.

The Host areas containing the AIDS virus are as follows, spleen, peripheral nervous system, macrophages, microglia tissue, lymph glands and finally the thymus. These 5 organs and structures can be considered to be contaminated and thus are rich in host virus and virus component templates components. The retrovirus with patient tissue material and virus can be captured from these listed locations for the vaccine preparation (Cohen et al., 1997, Immune Rev. 15931-48).

Investigation indicates that the best location for the vaccine administration is a 10 serial intraperitoneal injection. It appears that local edema and increased fluid causes a disturbance in the body's uptake regulation system, this fact caused poor uptake in subcutaneous injections and thus poor results against virus injection. Injections given through the peritoneum cavity intact 100% log positive life result The positive results suggest total uptake of the vaccine through the host body and an immune system response was possible. (Kamen, Nature, Vol. 192, No. 4806, pp. 986-987, Dec 9 1961).

Specific explanation for administration location of the vaccination preparation does not mean that other therapeutic ways and their routes are excluded from co-dissolution, for example, AZT Trademark to be taken orally in combination with acroleinized vaccine.

After reviewing this patent, it will be apparent to those specialized in the art of the subject that it will be possible to make certain slight variations or changes to the conclusion in the process and technique.

All examples and explanations in these patent inventions are intended to be indicative, illustrative. That is, it may undergo indications and illustrations shifting and supplementing information and correctness in view of the same theme of the prescribed invention. That is, the applicant requests that no absolute restrictions be imposed on the improvement of a firm existing idea; mainly. Independent Host specific Acroleinization of host virus 30 as an immune stimulant.

The applicant claims not to know of any existing means using Acrolein as prescribed herein; mainly the use of acrolein as an immune response mechanism against viruses. The applicant also claims not to know about a technique described as this which explains the adhesion mechanism for acrolein to the adult virus or parts thereof.

10 15 20 25 30 1015352 "

Claims (8)

1. Acrolein is the ideal reagent to make anti-virus vaccine. The instructions are as a result. 5 la. Acrolein (bulk) stabilized with hydroquinone: maximum hydroquinone 0.1 - 0.2 percent should be used as the base ingredient. 0.2 percent in 0.85 percent cold sterile saline solution must be distilled through a micro distillation unit on site. lb. Host equipment is taken from the host lymphatic system via "Ίη and Out" patient surgery, as discussed earlier in the description text. It removes 10 equipment is considered to be infected with or containing virus. This equipment serves as the template for Acrolein fixation. lc. Contaminated equipment is first finely crocheted with scissors, then a small amount of acrolein 0.2 just distilled chemical is added to the crocheted host equipment. The host material is then brought to a homogenate mixture status via a tissue homogenizer equipment (e.g., type Tri-R Teflon). ld. One will use the same distilled Acrolein as in step la. add again to the homogenate of step lc. until a suspension of 20 percent Acrolein versus over 80 percent homogenate mass is reached. le. The suspension of step 1d. is then stored in a light-skinned bottle. This bottle is kept at a normal laboratory room temperature for a period of time determined by the virus family and species. (e.g. 24 hours - 1 week). Then the same bottle ld. is stored in a cabinet at a temperature between 1-5 degrees Centigrade. This step completely determines inactivation of the virus. Research Data provides indicative that a waiting time is required and this is also virus specific. This step 25 also indicates the preservation of the result until needed for further treatment. There is yet another way to control the host virus in this step and inactivity. The Bottle of step ld. will undergo a treatment in which the bottle is put in the warm water bath at a constant temperature of 37 degrees centigrade. The bottles are provided with a cotton stopper that keeps things busy. This combination of homogenate and bottle in warm water requires an incubation time associated with the virus species. This can be shorter or longer in time (eg 1 day or 5 days). After the bath is finished, the bottle is kept in a carbon box with a constant 5 degree centigrade until further use is required. 1015352 lf. In this step inactivate homogenate from step 1 e. will have to undergo a serial dilution (eg 1: 5.1: 10) and mixing. For the serial dilution one will use sterile distilled water and a clinical sterile salt solution formulation. The mixture of water, homogenate and formulation together is a vaccination preparation which takes the "INJECTION", (eg hepatitis B virus formulated in widely adjuvant as explained in Francis et al .: Ann. Int. Med. 97: 362-6 (1982)). lg. Administration or injection of the INJECTION from step lf. should be done in the following way. The injection needle must be injected into the intraperitoneal cavity of the infecting guest from which the original virus, acrolein and tissue material are derived, see step 1b. 2. This vaccination technique is for viruses named HTLV-I, HTLV-II, HTLV-HI, HIV, HCV and all other lentivirus (s) that are yet to be discovered. This vaccination method is intended for all virus types. This vaccination method is intended for all prion species. This technique is not limited to the retrovirus family. This vaccination method is intended for many more families and classes of viruses including prions. 3. This invention contains three parts. a. Acrolienization (FAA), b. the location and regimen of administration of the vaccination, c. the use of the host of its own material. The immediate intention is to use this vaccination for AIDS patients as a novel way to solve the problem. 4. The use of Acrolein in the vaccine method (la. - lg.) Prescribed herein is necessary for the employment of the vaccine and immune system. Acrolein causes an immune system response that adult viruses can recognize as their micro components. In others, this invention is aware of the fact that acrolein foreign protein conjugation is necessary to produce circulating antibody. This particular antigen-antibody combination is essential. The use of acrolein in this invention is similar to the use of a camera that captures the entire family of virus that the host has. The acrolein photo serves as the antibody template. Despite the foregoing fact, acrolein is not the only chemical that will be able to elicit the host's immune defenses. There are certain NH2 and hydroxyl transformers that are publicly available that also emit an equal antigen and antibody signal that can trigger an immune system response. and not an autoimmune response can be used as part of the vaccination process. These chemicals have also been considered and are also contemplated in connection with the present invention. That is, all NH2 and hydroxl transformers that together with viruses do not exceed the phagocytic capacity that the host could ingest. This chemical compound is not autoimmune inducing and produces active antibody. Without the glucose layers of the virus spike, the virus cannot reach and bind to CD4 +. There are two main types of connections between Acrolein and the host virus. Minor connections are therefore irrelevant. First connection of acrolein to the host virus is via the aldehyde group of Acrolein. Acrolein searches for a hydraphobic fusion domain at the N terminus of the virus protein molecule that is usually seen in connection with glycoproteins. H20 is released in the reaction. See Formulas. The second type of linking between Acrolein and the virus is via the hydoxyl groups of the polysaccharides (including poly and mono) and the double bond of the acrolein molecule, Acrolein and the retrovirus polysaccharides, via a Michael type 1.4 addition reaction. See Formulas. In the case of the undeveloped intracytoplasmic virus, a standard three carbon compound conforming to the formulas indicated herein occurs. Acrolein connect to this end to the virus endings that are dominated by NH2 and hydroxyl groups. This compound also serves as a signal marker for the immune system and specific antibodies are also produced for this. See 20 Formulas. 5. The location of the administration and regimen of the vaccination is specific. The peritoneal cavity for intraperitoneal injection is the optimal location for vaccine. This route can be used regardless of the patient's age and race or condition. This vaccine injection administration will then be possible with a particular prescribed serial injection regimen (eg, 0.1 ml vaccine injection every seven days for a total of 4 times or anyway serial administration regimen). The dose during serial injections of the vaccination should take into account the host total weight per kilo and dose. Latent viruses may cause the need to administer multiple vaccination regimens to the host. 6. The locations on each host where the host specific virus can be isolated by surgery and extracticon are as follows; spleen, peripheral nervous system, macrophages, microglia tissue, lymph nodes and finally the thymus. For non-AIDS relevant viruses or prions, other locations and extraction methods may need to be used. 1015352 7. The Formulas for Fixation, Acroleinization and Acroleinized process are included. V. is a symbol representing virus. 8. Glycoprotein spikes have a tree-like morphological shape indicated in Figs 1 and 2. Polysaccharides form a region above the proteins where they are in the majority due to their joining and stereo coordination with the amino acids. Down polysaccharides are amino acid molecules that form the tweed region around the Spikes. Acrolein can penetrate and bind to the amino acids. The microscopic illustration of the conjugation can be seen in Fig. 1 and Fig. 2. The spike is further viewed in small size in two dimensions. It can be assumed that the sign 10 is two dimensional and that the virus is three dimensional. Indicated in numbers are the following: Fig. 1 can be considered as the Retrovirus and Acrolein composition. Fig.2 can be considered as the Spike and Acrolein. The indicated number means: 1. Acrolein chain, 2. Saccarhide chains, 3. Structural angular proteins, 4. Virus lipid 15 attachments. 20 25 30 1015352